11.99
price up icon8.61%   0.95
pre-market  Pre-market:  11.78   -0.21   -1.75%
loading
Kura Oncology Inc stock is traded at $11.99, with a volume of 3.81M. It is up +8.61% in the last 24 hours and up +37.19% over the past month. Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
See More
Previous Close:
$11.04
Open:
$11.22
24h Volume:
3.81M
Relative Volume:
2.16
Market Cap:
$1.06B
Revenue:
$71.64M
Net Income/Loss:
$-294.57M
P/E Ratio:
-3.5812
EPS:
-3.348
Net Cash Flow:
$-84.46M
1W Performance:
+9.30%
1M Performance:
+37.19%
6M Performance:
+20.26%
1Y Performance:
+111.09%
1-Day Range:
Value
$11.03
$12.00
1-Week Range:
Value
$10.65
$12.00
52-Week Range:
Value
$5.45
$12.49

Kura Oncology Inc Stock (KURA) Company Profile

Name
Name
Kura Oncology Inc
Name
Phone
(858) 500-8800
Name
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Name
Employee
260
Name
Twitter
@kuraoncology
Name
Next Earnings Date
2026-08-06
Name
Latest SEC Filings
Name
KURA's Discussions on Twitter

Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
KURA icon
KURA
Kura Oncology Inc
11.99 1.06B 71.64M -294.57M -84.46M -3.348
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
522.25 132.55B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
676.23 70.90B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
919.94 57.21B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
321.59 42.94B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
190.46 40.49B 742.00K -1.37B -1.07B -7.0731

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-14-26 Initiated Lake Street Buy
Sep-04-25 Initiated Guggenheim Neutral
Feb-06-25 Downgrade BTIG Research Buy → Neutral
Oct-24-24 Initiated UBS Buy
Oct-14-24 Downgrade Stifel Buy → Hold
Dec-22-23 Initiated Mizuho Buy
Aug-11-23 Initiated BofA Securities Buy
Jul-27-23 Initiated Scotiabank Sector Perform
May-17-23 Initiated BTIG Research Buy
Jan-31-23 Initiated Stifel Buy
Jul-12-22 Initiated Cantor Fitzgerald Overweight
Feb-15-22 Initiated Jefferies Buy
May-05-21 Resumed Credit Suisse Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Dec-07-20 Reiterated H.C. Wainwright Buy
Dec-03-20 Initiated Stifel Buy
Nov-05-20 Downgrade Piper Sandler Overweight → Neutral
Jul-07-20 Initiated Credit Suisse Outperform
May-05-20 Initiated Barclays Overweight
Jul-18-19 Initiated Deutsche Bank Buy
Nov-09-18 Initiated Piper Jaffray Overweight
Aug-01-18 Initiated H.C. Wainwright Buy
Oct-13-16 Resumed Leerink Partners Outperform
Jan-22-16 Initiated JMP Securities Mkt Outperform
Dec-30-15 Initiated Oppenheimer Outperform
Dec-16-15 Initiated Citigroup Buy
View All

Kura Oncology Inc Stock (KURA) Latest News

pulisher
Jul 07, 2026

Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story? - Yahoo Finance

Jul 07, 2026
pulisher
Jul 07, 2026

Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones - AD HOC NEWS

Jul 07, 2026
pulisher
Jul 03, 2026

Kura Oncology offers stock options to five new hires - Stock Titan

Jul 03, 2026
pulisher
Jul 02, 2026

KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill

Jul 02, 2026
pulisher
Jul 02, 2026

Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga

Jul 02, 2026
pulisher
Jul 01, 2026

Kura Oncology reports $5.8 million revenue in Q1 2026 - scanx.trade

Jul 01, 2026
pulisher
Jun 29, 2026

Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Kura Oncology, Inc.(NasdaqGS: KURA) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 26, 2026

Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Kura Oncology, Inc. Actuals & Estimates (HAM:KUR) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Kura Oncology, Inc. liabilities 2021-2025 - Statista

Jun 26, 2026
pulisher
Jun 26, 2026

Kura Oncology, Inc. Actuals & Estimates (DUS:KUR) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

KURA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits

Jun 25, 2026
pulisher
Jun 23, 2026

Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Jun 23, 2026
pulisher
Jun 23, 2026

Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness - 富途牛牛

Jun 23, 2026
pulisher
Jun 23, 2026

Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com - Investing.com Australia

Jun 23, 2026
pulisher
Jun 22, 2026

Form 4 Kura Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria

Jun 22, 2026
pulisher
Jun 22, 2026

Kura Oncology CMO Mollie Leoni sells $834,283 in common stock - Investing.com

Jun 22, 2026
pulisher
Jun 22, 2026

Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan - Stock Titan

Jun 22, 2026
pulisher
Jun 18, 2026

Understanding the Setup: (KURA) and Scalable Risk - Stock Traders Daily

Jun 18, 2026
pulisher
Jun 18, 2026

[144] Kura Oncology, Inc. SEC Filing - Stock Titan

Jun 18, 2026
pulisher
Jun 17, 2026

Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Kura Oncology Inc (KURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Kura Oncology Inc (KURA) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Kura Oncology Inc (KURA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 16, 2026

Kura Oncology Inc (KURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 16, 2026
pulisher
Jun 16, 2026

Kura Oncology Inc (KURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 16, 2026
pulisher
Jun 16, 2026

Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 16, 2026
pulisher
Jun 15, 2026

KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus

Jun 15, 2026
pulisher
Jun 15, 2026

Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com South Africa

Jun 15, 2026
pulisher
Jun 15, 2026

Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com

Jun 15, 2026
pulisher
Jun 15, 2026

LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo

Jun 15, 2026
pulisher
Jun 15, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 15, 2026
pulisher
Jun 13, 2026

Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA) - The Globe and Mail

Jun 13, 2026
pulisher
Jun 13, 2026

Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha

Jun 13, 2026
pulisher
Jun 12, 2026

H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jun 12, 2026
pulisher
Jun 12, 2026

KURA: Ziftomenib plus 7+3 shows high response and survival rates in AML, supporting phase III trials - TradingView

Jun 12, 2026
pulisher
Jun 12, 2026

KURA: Ziftomenib plus 7+3 shows high, durable remission and survival in AML, supporting phase III trials - TradingView

Jun 12, 2026
pulisher
Jun 12, 2026

KURA: Ziftomenib demonstrates high remission rates and strong safety in AML, supporting global expansion - TradingView

Jun 12, 2026
pulisher
Jun 12, 2026

Kura Oncology Inc EHA Investor Event Transcript - GuruFocus

Jun 12, 2026
pulisher
Jun 11, 2026

Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURA - TradingView

Jun 11, 2026
pulisher
Jun 11, 2026

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML - marketscreener.com

Jun 11, 2026
pulisher
Jun 11, 2026

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term - GlobeNewswire

Jun 11, 2026
pulisher
Jun 08, 2026

Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com

Jun 08, 2026
pulisher
Jun 07, 2026

The Technical Signals Behind (KURA) That Institutions Follow - Stock Traders Daily

Jun 07, 2026

Kura Oncology Inc Stock (KURA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$112.84
price up icon 1.17%
$57.80
price up icon 1.55%
$36.31
price up icon 2.60%
$79.77
price down icon 2.48%
ONC ONC
$308.96
price down icon 0.16%
$190.46
price up icon 0.25%
Cap:     |  Volume (24h):